Chengqian Yin

Chengqian Yin

Auto-generated profile, based on publicly available information

Chengqian Yin

Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
WCWeiwei Cui
Weiwei Cui
MGMeng Guo
Meng Guo
DLDong Liu
Dong Liu
PXPeng Xiao
Peng Xiao
CYChuancheng Yang
Chuancheng Yang
BCBo Chu
Bo Chu

20 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BHBin Huang
Bin Huang
HWHui Wang
Hui Wang
SLShuo Liu
Shuo Liu
MHMeng Hao
Meng Hao
DLDan Luo
Dan Luo
CYChengqian Yin
Chengqian Yin
S-palmitoylation is a reversible and widespread post-translational modification, but its role in the regulation of ferroptosis has been poorly understood. Here, we elucidate that GPX4, an essential regulator of ferroptosis, is reversibly palmitoylated on cysteine 66. The acyltransferase ZDHHC20 palmitoylates GPX4 and increases its protein stability. ZDHHC20 depletion or inhibition of protein palmitoylation by 2-BP sensitizes cancer cells to ferroptosis. Moreover, we identify APT2 as the depalmitoylase of GPX4. Genetic silencing or pharmacological inhibition of APT2 with ML349 increases GPX4 palmitoylation, thereby stabilizing the protein and conferring resistance to ferroptosis. Notably, disrupting GPX4 palmitoylation markedly potentiates ferroptosis in xenografted and orthotopically implanted tumor models, and inhibits tumor metastasis through blood vessels. In the chemically induced colorectal cancer model, knockout of APT2 significantly aggravates cancer progression. Furthermore, pharmacologically modulating GPX4 palmitoylation impacts liver ischemia–reperfusion injury. Overall, our findings uncover the intricate network regulating GPX4 palmitoylation, highlighting its pivotal role in modulating ferroptosis sensitivity.

22 May 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
BZBo Zhu
Bo Zhu
LTLiming Tang
Liming Tang
SCShuyang Chen
Shuyang Chen
CYChengqian Yin
Chengqian Yin
SPShiguang Peng
Shiguang Peng
PCPeng Cao
Peng Cao

1 February 2019 in Cell
Verified
Journal Article
Closed access
CYChengqian Yin
Chengqian Yin
BZBo Zhu
Bo Zhu
TZTing Zhang
Ting Zhang
TLTongzheng Liu
Tongzheng Liu
SCShuyang Chen
Shuyang Chen
RCRutao Cui
Rutao Cui

20 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCShuyang Chen
Shuyang Chen
CHChangpeng Han
Changpeng Han
XMXiao Miao
Xiao Miao
XLXin Li
Xin Li
CYChengqian Yin
Chengqian Yin
RCRutao Cui
Rutao Cui
Some genetic melanocortin-1 receptor (MC1R) variants responsible for human red hair color (RHC-variants) are consequently associated with increased melanoma risk. Although MC1R signaling is critically dependent on its palmitoylation primarily mediated by the ZDHHC13 protein-acyl transferase, whether increasing MC1R palmitoylation represents a viable therapeutic target to limit melanomagenesis in redheads is unknown. Here we identify a specific and efficient in vivo strategy to induce MC1R palmitoylation for therapeutic benefit. We validate the importance of ZDHHC13 to MC1R signaling in vivo by targeted expression of ZDHHC13 in C57BL/6J-MC1RRHCmice and subsequently inhibit melanomagenesis. By identifying APT2 as the MC1R depalmitoylation enzyme, we are able to demonstrate that administration of the selective APT2 inhibitor ML349 treatment efficiently increases MC1R signaling and represses UVB-induced melanomagenesis in vitro and in vivo. Targeting APT2, therefore, represents a preventive/therapeutic strategy to reduce melanoma risk, especially in individuals with red hair.

17 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
BZBo Zhu
Bo Zhu
SCShuyang Chen
Shuyang Chen
HWHongshen Wang
Hongshen Wang
CYChengqian Yin
Chengqian Yin
CHChangpeng Han
Changpeng Han
RCRutao Cui
Rutao Cui
The DOT1L histone H3 lysine 79 (H3K79) methyltransferase plays an oncogenic role in MLL-rearranged leukemogenesis. Here, we demonstrate that, in contrast to MLL-rearranged leukemia, DOT1L plays a protective role in ultraviolet radiation (UVR)-induced melanoma development. Specifically, the DOT1L gene is located in a frequently deleted region and undergoes somatic mutation in human melanoma. Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation. Importantly, in the absence of DOT1L, UVR-induced DNA damage is inefficiently repaired, so that DOT1L loss promotes melanoma development in mice after exposure to UVR. Mechanistically, DOT1L facilitates DNA damage repair, with DOT1L-methylated H3K79 involvement in binding and recruiting XPC to the DNA damage site for nucleotide excision repair (NER). This study indicates that DOT1L plays a protective role in UVR-induced melanomagenesis.